| Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 … J Rosenstock, J Frias, AM Jastreboff, Y Du, J Lou, S Gurbuz, MK Thomas, ... The Lancet 402 (10401), 529-544, 2023 | 127 | 2023 |
| DCAF1 regulates Treg senescence via the ROS axis during immunological aging Z Guo, G Wang, B Wu, WC Chou, L Cheng, C Zhou, J Lou, D Wu, L Su, ... The Journal of clinical investigation 130 (11), 5893-5908, 2020 | 92 | 2020 |
| RAS P21 protein activator 3 (RASA3) specifically promotes pathogenic T helper 17 cell generation by repressing T-helper-2-cell-biased programs B Wu, S Zhang, Z Guo, G Wang, G Zhang, L Xie, J Lou, X Chen, D Wu, ... Immunity 49 (5), 886-898. e5, 2018 | 20 | 2018 |
| Rad18 mediates specific mutational signatures and shapes the genomic landscape of carcinogen-induced tumors in vivo J Lou, Y Yang, Q Gu, BA Price, Y Qiu, Y Fedoriw, S Desai, LE Mose, ... NAR cancer 3 (1), zcaa037, 2021 | 16 | 2021 |
| Trans-lesion synthesis and mismatch repair pathway crosstalk defines chemoresistance and hypermutation mechanisms in glioblastoma X Cheng, J An, J Lou, Q Gu, W Ding, GN Droby, Y Wang, C Wang, Y Gao, ... Nature communications 15 (1), 1957, 2024 | 5 | 2024 |
| Learning latent heterogeneity for type 2 diabetes patients using longitudinal health markers in electronic health records J Lou, Y Wang, L Li, D Zeng Statistics in medicine 40 (8), 1930-1946, 2021 | 5 | 2021 |
| Single-Cell Transcriptomic Analysis of Dental Pulp and Periodontal Ligament Stem Cells Y Yang, T Alves, MZ Miao, YC Wu, G Li, J Lou, H Hasturk, TE Dyke, ... Journal of Dental Research 103 (1), 71-80, 2024 | 1 | 2024 |
| Evaluation of China’s Financial Risk Using Projection Pursuit Clustering Model and Its Positive Research J Lou, W Lou, X Yu Journal of Economics, Business and Management 2 (2), 139-146, 2014 | 1 | 2014 |
| 753-P: Eating Behavior in Adults with Type 2 Diabetes from a Phase 2 Study of Retatrutide C KANU, K BOYE, J LING POON, IA GOETZ, SE WILLIAMSON, J LOU, ... Diabetes 73 (Supplement_1), 2024 | | 2024 |
| 266-OR: Retatrutide, an Agonist of GIP, GLP-1, and Glucagon Receptors, Improves Markers of Pancreatic Beta-Cell Function and Insulin Sensitivity J ROSENSTOCK, T COSKUN, ML HARTMAN, J LOU, Q WU, YU DU, ... Diabetes 73 (Supplement_1), 2024 | | 2024 |
| Retatrutide, a triple GIP/GLP-1/glucagon receptor agonist, provides robust HbA1c and body weight reductions to people with type 2 diabetes: a 36--week, phase 2 study T Coskun, J Rosenstock, J Frias, AM Jastreboff, Y Du, J Lou, S Gurbuz, ... Diabetologie und Stoffwechsel 19 (S 01), P10. 01, 2024 | | 2024 |
| Estimating individualized treatment rules for multicategory type 2 diabetes treatments using electronic health records J Lou, Y Wang, L Li, D Zeng Statistics and its Interface 16 (4), 505, 2023 | | 2023 |
| Machine Learning Methods for Precision Medicine Using Patient Electronic Health Records and Mobile Sensor Data J Lou The University of North Carolina at Chapel Hill, 2021 | | 2021 |
